Business Description
Telix Pharmaceuticals Ltd
ISIN : AU000000TLX2
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 5.37 | |||||
Equity-to-Asset | 0.54 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | 0.3 | |||||
Interest Coverage | 5.09 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 17.66 | |||||
Beneish M-Score | -0.61 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 342.2 | |||||
3-Year FCF Growth Rate | 89.8 | |||||
3-Year Book Growth Rate | 17.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 192.16 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 37.84 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 45.93 | |||||
9-Day RSI | 51.96 | |||||
14-Day RSI | 54.74 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.99 | |||||
Quick Ratio | 0.87 | |||||
Cash Ratio | 0.46 | |||||
Days Inventory | 31.66 | |||||
Days Sales Outstanding | 41.05 | |||||
Days Payable | 91.68 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.9 | |||||
Shareholder Yield % | -0.17 |
Profitability Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 63.38 | |||||
Operating Margin % | 12.49 | |||||
Net Margin % | 7.72 | |||||
FCF Margin % | 3.35 | |||||
ROE % | 23.46 | |||||
ROA % | 10.14 | |||||
ROIC % | 21.54 | |||||
3-Year ROIIC % | 64.16 | |||||
ROC (Joel Greenblatt) % | 214.69 | |||||
ROCE % | 22 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 141.68 | |||||
Forward PE Ratio | 86.72 | |||||
PE Ratio without NRI | 141.68 | |||||
Price-to-Owner-Earnings | 1005.24 | |||||
PS Ratio | 10.95 | |||||
PB Ratio | 17.46 | |||||
Price-to-Tangible-Book | 1309.5 | |||||
Price-to-Free-Cash-Flow | 335.08 | |||||
Price-to-Operating-Cash-Flow | 142.64 | |||||
EV-to-EBIT | 107.17 | |||||
EV-to-EBITDA | 96.53 | |||||
EV-to-Revenue | 11.06 | |||||
EV-to-FCF | 327.08 | |||||
Price-to-Graham-Number | 100.73 | |||||
Earnings Yield (Greenblatt) % | 0.93 | |||||
FCF Yield % | 0.3 |